Increased frequency of minimal homozygous deletions is associated with poor prognosis in primary malignant melanoma patients

2014 ◽  
Vol 53 (6) ◽  
pp. 487-496 ◽  
Author(s):  
Sebastiana Boi ◽  
Toma Tebaldi ◽  
Angela Re ◽  
Chiara Cantaloni ◽  
Valentina Adami ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Poor Prognosis ◽  
Primary Malignant Melanoma ◽  
Melanoma Patients ◽  
Homozygous Deletions

Decreased Serum Tryptophan Concentration Predicts Poor Prognosis in Malignant Melanoma Patients

Dermatology ◽  
2006 ◽  
Vol 214 (1) ◽  
pp. 8-14 ◽  
Author(s):  
Georg Weinlich ◽  
Christian Murr ◽  
Laura Richardsen ◽  
Christiana Winkler ◽  
Dietmar Fuchs
Keyword(s):  
Malignant Melanoma ◽  
Poor Prognosis ◽  
Tryptophan Concentration ◽  
Melanoma Patients

scholarly journals Primary malignant melanoma of the esophagus. Literature review and clinical case

2020 ◽  
Vol 9 (4) ◽  
pp. 42-48
Author(s):  
N.  M. Kiselev ◽  
N.  V. Bobrov ◽  
D.  M. Kuchin ◽  
G.  G. Torgomyan ◽  
L.  V. Shkalova ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Literature Review ◽  
Rare Disease ◽  
World Literature ◽  
Poor Prognosis ◽  
Clinical Case ◽  
Diagnosis And Treatment ◽  
Primary Malignant Melanoma ◽  
The World ◽  
Resectable Esophageal

Primary malignant melanoma of the esophagus is a rare disease with an aggressive course and poor prognosis. This article presents a review of the world literature on this specific disease, including incidence statistics, modern principles of diagnosis and treatment, as well as a clinical case of a patient with resectable esophageal melanoma.

Intramedullary Melanocytoma: Case Report and Review of Literature

2009 ◽  
Vol 95 (3) ◽  
pp. 389-393 ◽  
Author(s):  
Riccardo Caruso ◽  
Luigi Marrocco ◽  
Venceslao Wierzbicki ◽  
Maurizio Salvati
Keyword(s):  
Cerebrospinal Fluid ◽  
Case Report ◽  
Malignant Melanoma ◽  
Rare Case ◽  
Metastatic Spread ◽  
Primary Malignant Melanoma ◽  
Review Of Literature ◽  
Total Removal ◽  
Melanoma Patients

We report on a very rare case of dorsal intramedullary melanocytoma in a 62-year-old man. The tumor was resected and gross total removal was achieved. During a 2-year follow-up period in which no radiotherapy was given, the tumor did not recur. We review the literature on these tumors and present disease criteria to distinguish melanocytoma from primary malignant melanoma. Patients and investigators should be cautioned that an intramedullary melanocytoma may recur and give rise to metastatic spread via the cerebrospinal fluid.

scholarly journals Nevus-Like Appearance of Primary Malignant Melanoma of the Esophagus

2009 ◽  
Vol 2009 ◽  
pp. 1-3
Author(s):  
Min-Jung Kang ◽  
Sun Young Yi
Keyword(s):  
Malignant Melanoma ◽  
Poor Prognosis ◽  
Malignant Disease ◽  
Esophageal Neoplasms ◽  
Epigastric Pain ◽  
Distal Portion ◽  
Primary Malignant Melanoma ◽  
Advanced Stages ◽  
Mucosal Lesions ◽  
Tissue Specimens

The primary malignant melanoma of the esophagus (PMME) is a rare malignant disease, accounting for only 0.1–0.2% of all esophageal neoplasms, and the majority of the patients are diagnosed at advanced stages with poor prognosis. We present here a case of 56-year-old woman with epigastric pain and her endoscopic finding revealed several flat and black pigmented mucosal lesions within the distal portion of the esophagus which looked like flat nevus. The histopathology and immunohistochemical profile of the tissue specimens were diagnostic of malignant melanoma.

scholarly journals A Case of Malignant Melanoma Arising in Mediastinal Malignant Teratoma

2018 ◽  
Vol 2018 ◽  
pp. 1-5
Author(s):  
Ikuma Nozaki ◽  
Yumi Tone ◽  
Junko Yamanaka ◽  
Hideko Uryu ◽  
Yuko Shimizu-Motohashi ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Malignant Transformation ◽  
Poor Prognosis ◽  
Mediastinal Mass ◽  
Bone Biopsy ◽  
Systematic Evaluation ◽  
Anterior Mediastinal Mass ◽  
Malignant Teratoma ◽  
Experienced Pain

We report about a 14-year-old boy who presented with an anterior mediastinal mass that was diagnosed as malignant teratoma. Surgical resection was performed along with pre- and postoperative chemotherapy. Although elevated alpha-fetoprotein became negative, he experienced pain in his right hip joint 3 months after resection. Systematic evaluation revealed multiple locations of metastasis, and the pathological diagnosis based on bone biopsy was malignant melanoma originating from malignant teratoma, which rapidly progressed. He died 15 months after diagnosis of the original malignant teratoma. Diagnosing and treating malignant transformation of teratoma, including malignant melanoma, is difficult because it is very rare. To our knowledge, this is the second reported case of malignant melanoma arising from a mediastinum malignant teratoma, with both cases having a poor prognosis. In addition to the follow-up of tumor markers, systematic evaluation, including imaging, should be considered even after remission to monitor malignant transformation of teratoma. We expect to establish a successful therapy and improve mortality rate after more such cases are accumulated.

scholarly journals Primary malignant melanoma of the lacrimal sac

2012 ◽  
Vol 2012 (aug09 1) ◽  
pp. bcr2012006349-bcr2012006349 ◽  
Author(s):  
Y.-J. Li ◽  
S.-J. Zhu ◽  
H. Yan ◽  
J. Han ◽  
D. Wang ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Primary Malignant Melanoma ◽  
Lacrimal Sac

scholarly journals Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST

2021 ◽  
Author(s):  
Kazuhiro Kitajima ◽  
Tadashi Watabe ◽  
Masatoyo Nakajo ◽  
Mana Ishibashi ◽  
Hiromitsu Daisaki ◽  
...  
Keyword(s):  
Metabolic Disease ◽  
Malignant Melanoma ◽  
Fdg Pet ◽  
Immune Checkpoint Inhibitor ◽  
Metabolic Response ◽  
Checkpoint Inhibitor ◽  
Response Evaluation ◽  
Pet Ct ◽  
Melanoma Patients ◽  
Fdg Pet Ct

Abstract Objective In malignant melanoma patients treated with immune checkpoint inhibitor (ICI) therapy, three different FDG-PET criteria, European Organization for Research and Treatment of Cancer (EORTC), PET Response Criteria in Solid Tumors (PERCIST), immunotherapy-modified PERCIST (imPERCIST), were compared regarding response evaluation and prognosis prediction using standardized uptake value (SUV) harmonization of results obtained with various PET/CT scanners installed at different centers. Materials and methods Malignant melanoma patients (n = 27) underwent FDG-PET/CT examinations before and again 3 to 9 months after therapy initiation (nivolumab, n = 21; pembrolizumab, n = 6) with different PET scanners at five hospitals. EORTC, PERCIST, and imPERCIST criteria were used to evaluate therapeutic response, then concordance of the results was assessed using Cohen’s κ coefficient. Log-rank and Cox methods were employed to determine progression-free (PFS) and overall (OS) survival. Results Complete metabolic response (CMR)/partial metabolic response (PMR)/stable metabolic disease (SMD)/progressive metabolic disease (PMD) with harmonized EORTC, PERCIST, and imPERCIST was seen in 3/5/4/15, 4/5/3/15, and 4/5/5/13 patients, respectively. Nearly perfect concordance between each pair of criteria was noted (κ = 0.939–0.972). Twenty patients showed progression and 14 died from malignant melanoma after a median 19.2 months. Responders (CMR/PMR) showed significantly longer PFS and OS than non-responders (SMD/PMD) (harmonized EORTC: p < 0.0001 and p = 0.011; harmonized PERCIST: p < 0.0001 and p = 0.0012; harmonized imPERCIST: p < 0.0001 and p = 0.0012, respectively). Conclusions All harmonized FDG-PET criteria (EORTC, PERCIST, imPERCIST) showed accuracy for response evaluation of ICI therapy and prediction of malignant melanoma patient prognosis. Additional studies to determine their value in larger study populations will be necessary.

Sign in / Sign up

Export Citation Format

Share Document